COVID-19
Sections
-
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Ge...
1/04/2020
Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19 -
Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Sever...
1/04/2020
Kiniksa Pharmaceuticals, Ltd., today announced early evidence of treatment response with mavrilimumab, an investigational fully-human monoclonal antibody that targets granulocyte macrophage colony stimulating factor receptor alpha (GM-CSFRα), in a treatment protocol in patients with severe corona... -
GILEAD SCIENCES ANNOUNCES TWO PHASE 3 RANDOMISED STUDIES TO EVALUATE THE SAFETY AND ANTIVIRAL ACT...
1/04/2020
Gilead Sciences announced today that the company has initiated two phase 3 randomised studies to evaluate the safety and efficacy of its investigational treatment remdesivir in patients with moderate to severe COVID-19 (coronavirus). -
Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020
-
As the novel coronavirus (COVID-19) pandemic continues to spread globally, virtual platforms will experience an extra boost after already having a transformational impact on the entire healthcare landscape even before the outbreak, says GlobalData, a leading data and analytics company.
-
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the ...
26/03/2020
AstraZeneca is donating nine million face masks to support healthcare workers around the world as they respond to the COVID-19 (novel coronavirus) global pandemic. AstraZeneca has partnered with the World Economic Forum’s COVID Action Platform, created with the support of the World Health Organis... -
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19.
-
Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specific...
26/03/2020
Grifols today announces that it has entered into a formal collaboration with the United States Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA) and other Federal public health agencies to collect plasma from convalescent COVID-19 patients... -
Medi-Immune Ltd. have today (25-03-20) revealed their ProtectivAir® compact, wearable, breathing device which will protect front-line healthcare staff and those working in biologically-compromised environments.
-
For those of us in an industry who comprehend the lengthy and expensive process of drug discovery, testing and trials, the speed and urgency at which our industry is moving to develop an effective vaccine and treatment is something to be proud of
-
The coronavirus pandemic is creating stress in the global population. Empty store shelves, fear about the disease and quarantine or self-isolation can negatively impact depression and anxiety.